HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TSE research

This article was originally published in The Rose Sheet

Executive Summary

FDA center for Food Safety & Applied Nutrition to dedicate roughly $500,000 in fiscal 2002 to fund collaborative research on prevention of transmissible spongiform encephalopathies in cosmetics, food additives, dietary supplements, CFSAN announces in request for applications published in April 11 Federal Register. Project aims to promote "development of surrogate and techniques to facilitate studies that will reliably predict the ability of treatments or manufacturing processes to inactivate the infectivity and biological activity of prions associated" with TSE diseases, CFSAN says. FDA will support collaborative agreements ranging from $100,000 to $250,000 per year for up to four years. Applications are due June 10...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel